PRRT for patients with neuroendocrine tumor: how does the reduction in the number of SPECT CT studies affect tumor and OAR dosimetry?. (December 2021) - Tonini, E.; Panareo, S.; Longo, M.; Longo, L.; Urso, L.; Caracciolo, M.; Uccelli, L.; Cittanti, C.; Turra, A.; Bartolomei, M.